Company Encyclopedia
View More
name
Evotec SE
EVO.US
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore.
744.61 B
EVO.USMarket value -Rank by Market Cap -/-

Financial Score

11/11/2025 Update
D
Life Sciences Tools and ServicesIndustry
Industry Ranking46/61
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-17.98%E
    • Profit Margin-21.02%D
    • Gross Margin-0.04%E
  • Growth ScoreD
    • Revenue YoY-0.50%D
    • Net Profit YoY5.16%C
    • Total Assets YoY-6.48%D
    • Net Assets YoY-13.22%E
  • Cash ScoreD
    • Cash Flow Margin-475.74%E
    • OCF YoY-0.50%D
  • Operating ScoreC
    • Turnover0.4C
  • Debt ScoreC
    • Gearing Ratio54.86%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Evotec SE unveils new presentation highlighting AI-driven drug discovery and advanced technology platforms

    Evotec SE has introduced a new presentation focusing on AI-driven drug discovery and advanced technology platforms. The presentation details Evotec's commercial model, which includes contract research services and partnerships, and highlights its integrated operational platform and expertise in drug development. It also addresses market trends, such as cautious spending in biotech and growth in the biologics CDMO market. Evotec's AI-enhanced platforms aim to improve R&D efficiency and support high-value partnerships. The full presentation is accessible via a provided link.

    Reuters·
    US
    EVO
    -0.67%
    Reuters·
    US
    EVO
    -0.67%

    Evotec SE Launches Share Repurchase Program to Enhance Shareholder Value

    Evotec SE has launched a share repurchase program to buy back up to 290,000 shares for a total cost of up to EUR 3 million, running from November 7 to December 17, 2025. This initiative aims to enhance shareholder value and support employee retention by converting repurchased shares into American Depositary Shares. Despite a recent analyst rating of Buy with a $7.00 price target, Evotec faces significant financial challenges, including negative profitability and cash flow issues, leading to a Neutral rating from TipRanks' AI Analyst.

    Tip Ranks·
    US
    EVO
    -0.67%
    Tip Ranks·
    US
    EVO
    -0.67%

    Evotec AG Earnings Call: Resilience Amidst Challenges

    Evotec AG's earnings call highlighted resilience despite challenges, with a 7% revenue decline to EUR 535.1 million, primarily due to difficulties in the Drug Discovery & Preclinical Development (D&PD) segment. However, the Biologics segment grew 11% to EUR 143.2 million, bolstered by a significant deal with Sandoz expected to yield over $650 million. Cost reduction initiatives are ahead of schedule, targeting EUR 60 million by 2025. Despite current hurdles, Evotec projects group revenues of EUR 760-800 million and positive EBITDA for 2025, indicating a strategic path forward.

    Tip Ranks·
    US
    EVO
    -0.67%
    Tip Ranks·
    US
    EVO
    -0.67%

    Evotec AG: Strategic Sale and AI/ML Expansion Drive Buy Rating Amidst Growth Uncertainties

    Brendan Smith has issued a Buy rating for Evotec AG, citing the strategic sale of its JEB manufacturing facility to Sandoz, expected to generate around €650 million. This non-dilutive capital is vital for the company's financial stability amid macroeconomic challenges. While the sale raises concerns about the JEB segment's long-term growth, Evotec's expansion into AI/ML presents medium-term growth potential. Despite Q3 revenue misses due to slowed contract activity, early recovery signs in some segments may bolster future growth.

    Tip Ranks·
    US
    EVO
    -0.67%
    Tip Ranks·
    US
    EVO
    -0.67%

    Evotec shares are trading lower after the company reported worse-than-expected Q3 sales results.

    benzinga_article·
    US
    EVO
    -0.67%
    benzinga_article·
    US
    EVO
    -0.67%